Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Six-month, Randomized, Open-label, Parallel-group Comparison of SAR341402 to NovoLog®/NovoRapid® in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine, With a 6-month Safety Extension Period

NCT03211858 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT03211858
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03211858 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Six-month, Randomized, Open-label, Parallel-group Comparison of SAR341402 to NovoLog®/NovoRapid® in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine, With a 6-month Safety Extension Period
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
August 2, 2017
Completion date
January 12, 2019
Enrollment
597 (actual)
Sites
82

Conditions

As the registry lists them; a condition with its own page is linked.

type 1 diabetes mellitus-type 2 diabetes mellitus